Martin Babler - Net Worth and Insider Trading
Martin Babler Net Worth
The estimated net worth of Martin Babler is at least $6 Million dollars as of 2024-12-26. Martin Babler is the President, CEO of Principia Biopharma Inc and owns about 58,344 shares of Principia Biopharma Inc (PRNB) stock worth over $6 Million. Details can be seen in Martin Babler's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Martin Babler has not made any transactions after 2020-06-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Martin Babler
Martin Babler Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Martin Babler owns 6 companies in total, including Principia Biopharma Inc (PRNB) , Neoleukin Therapeutics Inc (NLTX) , and ZS Pharma Inc (ZSPH) among others .
Click here to see the complete history of Martin Babler’s form 4 insider trades.
Insider Ownership Summary of Martin Babler
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
PRNB | Principia Biopharma Inc | 2020-09-28 | director & President & CEO |
NLTX | Neoleukin Therapeutics Inc | 2020-09-08 | director |
ZSPH | ZS Pharma Inc | 2015-12-17 | director |
2008-05-22 | director | ||
2021-07-19 | director | ||
2021-01-06 | director |
Martin Babler Latest Holdings Summary
Martin Babler currently owns a total of 1 stock. Martin Babler owns 58,344 shares of Principia Biopharma Inc (PRNB) as of June 23, 2020, with a value of $6 Million.
Latest Holdings of Martin Babler
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
PRNB | Principia Biopharma Inc | 2020-06-23 | 58,344 | 100.05 | 5,837,317 |
Holding Weightings of Martin Babler
Martin Babler Form 4 Trading Tracker
According to the SEC Form 4 filings, Martin Babler has made a total of 2 transactions in Principia Biopharma Inc (PRNB) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Principia Biopharma Inc is the sale of 15,000 shares on June 23, 2020, which brought Martin Babler around $927,900.
Insider Trading History of Martin Babler
- 1
Martin Babler Trading Performance
Martin Babler Ownership Network
Martin Babler Owned Company Details
What does Principia Biopharma Inc do?
Who are the key executives at Principia Biopharma Inc?
Martin Babler is the director & President & CEO of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .
Principia Biopharma Inc (PRNB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Principia Biopharma Inc Insider Transactions
Martin Babler Mailing Address
Above is the net worth, insider trading, and ownership report for Martin Babler. You might contact Martin Babler via mailing address: C/o Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge Ma 02139.